Personalized Search
Displaying 1 - 20 of 69
-
PURPOSE: Patients who have cancer have leveraged the Internet to gain a better understanding of their disease and connect across geographic boundaries with others facing the same challenges. Online cancer communities have developed into resources that highlight new research and evolving care pathways. Combined with increasing health literacy and social media, they have enabled some patients to...Article last updated May 30, 2023.Node ID (debugging only): 9951
-
June 2, 2022 - Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant – - Omidubicel has Orphan Drug Designation and Breakthrough Therapy Designation - BOSTON--(BUSINESS WIRE)--Jun. 2, 2022-- Gamida Cell Ltd. (Nasdaq: GMDA), the...Article last updated May 30, 2023.Node ID (debugging only): 9976
-
Key Points Structural racism (SR) assessed by census tract variables accounts for nearly all Black-white and Hispanic-white disparity in AML survival. Structural Racism is a stronger mediator of survival disparities than molecular features, co-morbidities, healthcare access and treatment. Non-Hispanic Black (NHB) and Hispanic patients with acute myeloid leukemia (AML) have higher mortality rates...Article last updated May 30, 2023.Node ID (debugging only): 9949
-
Driven by his mother’s advice and his father’s memory, Richard M. Stone, MD, rose to become a global leader in leukemia care and research. Growing up, Richard M. Stone, MD, thought he was going to be an attorney like his father, but his direction in life changed when he was 15. His father, Benjamin, developed kidney cancer when Stone was just 5 years old, and 10 years later, the disease...Article last updated May 30, 2023.Node ID (debugging only): 9935
-
This is the first episode of our new podcast. Leigh Clark, Patient Educator, describes the bone marrow failure journey and how AAMDSIF can help!Podcast Episode last updated November 2, 2022.Node ID (debugging only): 8157
-
FOR IMMEDIATE RELEASE Aplastic Anemia and MDS International Foundation Announces 2021 Research Grant Recipients (BETHESDA, MD) February 11, 2022. The Aplastic Anemia and MDS International Foundation announces the two recipients of the 2021 Research Awards. For over 30 years, AAMDSIF has provided financial support for research that leads to new insights into the causes of bone marrow...Article last updated February 18, 2022.Node ID (debugging only): 9918
-
Abstract Diagnosis of myelodysplastic syndrome (MDS) mainly relies on a manual assessment of the peripheral blood and bone marrow cell morphology. The WHO guidelines suggest a visual screening of 200 to 500 cells which inevitably turns the assessor blind to rare cell populations and leads to low reproducibility. Moreover, the human eye is not suited to detect shifts of cellular properties of...Article last updated February 18, 2022.Node ID (debugging only): 9916
-
Eltrombopag, an FDA-approved non-peptidyl thrombopoietin receptor agonist is clinically used for the treatment of aplastic anemia, a disease characterized by hematopoietic stem cell failure and pancytopenia, to improve platelet counts and stem cell function. Eltrombopag treatment results in durable tri-lineage hematopoietic expansion in patients. Some of the eltrombopag hematopoietic activity has...Article last updated January 28, 2022.Node ID (debugging only): 9897
-
The mRNA COVID-19 Vaccines Are Safe and Effective for Most Patients with Cancer For most patients with cancer, the mRNA COVID-19 vaccines are safe and effective. This article explains the results of the first study that evaluated the safety and effectiveness of the mRNA vaccines in patients with solid cancers, such as lung, breast, or prostate cancer. November 2021 – Lung Cancer Laura Morgan The...Article last updated January 24, 2022.Node ID (debugging only): 9849
-
Myelodysplastic syndromes (MDS) and neutropenia were both found to be strong, independent predictors of severe COVID-19 illness in patients with acute leukemia or MDS who developed COVID-19, according to data from the American Society of Hematology (ASH) RC COVID-19 Registry for Hematology presented at the ASH Annual Meeting and Exposition 2021. However, active disease alone for hospitalized...Article last updated January 11, 2022.Node ID (debugging only): 9850
-
VOYDEYA is a prescription medicine used along with ravulizumab or eculizumab to treat breakdown of red blood cells that takes place outside of blood vessels (extravascular hemolysis), in adults with paroxysmal nocturnal hemoglobinuria (PNH). It is not known if VOYDEYA is safe and effective in children. What is VOYDEYA? VOYDEYA is a prescription medicine used along with...Drug last updated April 26, 2024.Node ID (debugging only): 10540
-
EMPAVELI® is the first PNH treatment that binds to complement protein C3. It was approved by the Food and Drug Administration in May 2021 for treating adult patients with paroxysmal nocturnal hemoglobinuria (PNH). EMPAVELI is given skin (subcutaneously) by using the Empaveli injector or with an infusion pump 2 times a week. What is EMPAVELI®? Empaveli® (previously known as pegacetacoplan) is the...Drug last updated April 26, 2024.Node ID (debugging only): 9811
-
MDS, or Myelodysplastic syndromes, are a family of rare disorders in which the bone marrow fails to make enough healthy red blood cells, white blood cells or platelets. This is caused by bone marrow producing lots of underdeveloped, or immature, cells that have an abnormal shape, size or look. These are called blast cells. Most experts agree that MDS is a form of blood and bone marrow cancer....Page last updated April 18, 2024.Node ID (debugging only): 4315
-
Subscribers to the GVHD Interactive Provider Network mailing list receive: Updates about events and trainings Login information to participate in the online discussions Access to the ECHO platform Subscribers may opt out and unsubscribe at any time. Please find the required and optional fields below.Webform last updated April 12, 2024.Node ID (debugging only): 9953
-
AAMDSIF provides educational materials for patients and healthcare professionals written in plain language and reviewed by highly respected and recognized medical doctors who are experts in bone marrow failure diseases. If you are a patient: please fill out the form below and a complete information packet will be mailed to you free of charge. Alternatively you can...Webform last updated April 12, 2024.Node ID (debugging only): 8326
-
AAMDSIF receives support from corporate partners who invest in advancing our mission. Thanks to their financial contributions, we are able to provide answers, support, and hope to patients, their families, and healthcare professionals entrusted with providing quality care. AAMDSIF Corporate Partners provide financial and in-kind support of programming through sponsorships and grants. AAMDSIF...Page last updated April 4, 2024.Node ID (debugging only): 10356
-
Deferiprone is in a class of medications called iron chelators. It works by attaching to iron in the body so that it can be excreted (removed from the body). Deferiprone comes in a pill form and is taken by mouth. Deferiprone is approved for use in Europe. Researchers in the U.S. are studying deferiprone for treating iron overload in patients with thalassemia. Deferiprone binds with iron in the...Drug last updated April 4, 2024.Node ID (debugging only): 4424
-
Venetoclax is used to treat chronic lymphocytic leukemia or small lymphocytic leukemia in adults. Venetoclax is used alone or in combination with other cancer medicines to treat these conditions.Drug last updated April 4, 2024.Node ID (debugging only): 9609
-
Currently it is approved by the U.S. Food and Drug Administration (FDA) for use in treating a skin disease associated with leprosy. Thalidomide is being studied, either as a single agent or in combination with other medicines, for treating of myelodysplastic syndromes (MDS). These clinical trials are studying the effectiveness and safety of the drug. A pilot study of thalidomide, published in...Drug last updated April 4, 2024.Node ID (debugging only): 4431
-
Sabatolimab (MBG453) is a novel immuno-myeloid therapy that binds to TIM-3 on immune cells, facilitating antileukemic immune activation and phagocytic killing of leukemic cells. Sabatolimab also binds to TIM-3 on leukemic cells, potentially impeding self-renewal of LSCs via inhibition of TIM3-galectin-9.Drug last updated April 4, 2024.Node ID (debugging only): 9942